International Journal of Health Policy and Management

International Journal of Health Policy and Management

Impact of “Sambhav” Program (Financial Assistance and Counselor Services) on Hepatitis C Pegylated Interferon Alpha Treatment Initiation in India

Document Type : Original Article

Authors
Ajit Sood 1
Vandana Midha 2
Shivalingappa S. Halli 3
Vikram Narang 4
Ramit Mahajan 1
Varun Mehta 1
Kirandeep Kaur 5
Vijay Surlikar 6
Subodh Kanchi 6
Dharmatma Singh 1
1 Department of Gastroentrology, Dayanand Medical College and Hospital (DMCH), Ludhiana, India
2 Department of Internal Medicine, Dayanand Medical College and Hospital (DMCH), Ludhiana, India
3 University of Manitoba, Winnipeg, MN, Canada
4 Department of Pathology, Dayanand Medical College & Hospital (DMCH), Ludhiana, India
5 Department of Pharmacology, Dayanand Medical College and Hospital, Ludhiana, India
6 MSD Pharmaceutical Pvt Ltd, Bandra, India
10.15171/ijhpm.2018.84
Abstract
Background
Financial constraints, social taboos and beliefs in alternative medicine are common reasons for delaying or not considering treatment for hepatitis C in India. The present study was planned to analyze the impact of non-banking interest free loan facility in patients affected with hepatitis C virus (HCV) in North India.
 
Methods
This one year observational, retrospective study was conducted in Department of Gastroenterology (January 2012-December 2013), Dayanand Medical College and Hospital Ludhiana, to evaluate the impact of program titled “Sambhav” (which provided non-banking financial assistance and counselor services) on treatment initiation and therapeutic compliance in HCV patients. Data of fully evaluated patients with chronic hepatitis, and/or cirrhosis due to HCV infection who were treated with Peginterferon alfa and ribavirin (RBV) combination during this duration (2012-2013) was collected from patient medical records and analyzed. In the year 2012, eligible patients who were offered antiviral treatment paid for treatment themselves, while in 2013, ‘Sambhav’ program was launched and this provided interest free financing by non-banking financial company (NBFC) for the treatment of HCV in addition to free counselor services for disease management. The treatment initiation and compliance rates were compared between the patients (n = 585) enrolled in 2013 who were offered ‘Sambhav’ assistance and those enrolled in 2012 (n = 628) when ‘Sambhav’ was not available.
 
Results
Introduction of Sambhav program improved the rates of treatment initiation (59% in 2013 vs. 51% in 2012, P = .004). Of the 585 eligible patients offered ‘Sambhav’ assistance in 2013, 233 patients (39.8%) applied but 106/233 (45.4%) received assistance. Antiviral therapy was started in 93/106 (87.7%) of these patients, while only 52 (42.5%) of 127 patients whose applications were rejected underwent treatment. Compliance to antiviral therapy also improved with the introduction of ‘Sambhav’ program (87.7% vs. 74.1%, P = .001).
 
Conclusion
‘Sambhav’ program had significant impact on the initiation of antiviral therapy by overcoming the financial hurdles. The free counselor services helped to mitigate social taboos and imparted adequate awareness about the disease to the patients. Initiatives like ‘Sambhav’ can be utilized for improving healthcare services in developing countries, especially for chronic diseases.

Highlights

 

Watch the Video Summary here.

Keywords
Sambhav Program
Hepatitis C
Pegylated Interferon Gamma
Treatment Access
India
Subjects

 

 

  1. Jhabvala R, Subramanya RKA. The Unorganised Sector: Work Security and Social Protection. New Delhi: Sage; 2000.
  2. Ahmad E, Dreze J, Hills J, Sen A, eds. Social Security in Developing Countries. Oxford: Clarendon Press; 1991.
  3. Gumber A, Shariff A, Duggal R, Alam M. Health Care Financing and Insurance: Perspective for the Ninth Plan, 1997-2002. Margin. 1999;31(2):38-68.
  4. Gumber A. Burden of disease and cost of ill health in India: setting priorities for health interventions during the Ninth Plan. Margin. 1997;29(2):133-172.
  5. Gumber A, Kulkarani V. Health insurance for workers in the informal sector: Detail results from a pilot study. New Delhi: National Council of Applied Economic Research; 2000.
  6. Sood A, Sarin SK, Midha V, et al. Prevalence of hepatitis C virus in a selected geographical area of northern India: a population based survey. Indian J Gastroenterol. 2012;31(5):232-236. doi:10.1007/s12664-012-0251-8
  7. Puri P, Anand AC, Saraswat VA, et al. Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India. J Clin Exp Hepatol. 2014;4(2):117-140. doi:10.1016/j.jceh.2014.06.001
  8. Sood A, Midha V, Mahajan R, et al. Results of sofosbuvir-based combination therapy for chronic hepatitis C cohort of Indian patients in real-life clinical practice. J Gastroenterol Hepatol. 2017;32(4):894-900. doi:10.1111/jgh.13628
  9. Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: A review from the patient's perspective. Ther Clin Risk Manag. 2008;4(1):269-286.
  10. Selvaraj S, Karan AK. Why publicly-financed health insurance schemes are ineffective in providing financial risk protection. Econ Polit Wkly. 2012;47(11):60-68.
  11. Selvaraj S, Subramanian SV. Financial risk protection & chronic disease care. Indian J Med Res. 2012;136(4):544-546.
International Journal of Health Policy and Management
Volume 7, Issue 12
December 2018
Pages 1138-1144

  • Received Date 09 December 2017
  • Revised Date 26 August 2018
  • Accepted Date 26 August 2018
  • First Published Date 01 December 2018
  • Published Date 01 December 2018